

## Armata Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference

MARINA DEL REY, Calif., March 16, 2021 /[PRNewswire](#)/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the Oppenheimer 31<sup>st</sup> Annual Healthcare Conference taking place virtually March 16-18, 2021.

Management is scheduled to present at 3:10pm ET on Wednesday, March 17.

### About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

### Media Contacts:

#### At Armata:

Steve Martin  
Armata Pharmaceuticals, Inc.  
[ir@armatapharma.com](mailto:ir@armatapharma.com)  
858-800-2492

#### Investor Relations:

Joyce Allaire  
LifeSci Advisors, LLC  
[jallaire@lifesciadvors.com](mailto:jallaire@lifesciadvors.com)  
212-915-2569

SOURCE Armata Pharmaceuticals, Inc.

---

<https://investor.armatapharma.com/2021-03-16-Armata-Pharmaceuticals-to-Present-at-the-Oppenheimer-31st-Annual-Healthcare-Conference>